• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哌醋甲酯在双相情感障碍中的自然主义长期使用。

Naturalistic long-term use of methylphenidate in bipolar disorder.

作者信息

Lydon Eric, El-Mallakh Rif S

机构信息

Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY 40202, USA.

出版信息

J Clin Psychopharmacol. 2006 Oct;26(5):516-8. doi: 10.1097/01.jcp.0000236655.62920.dc.

DOI:10.1097/01.jcp.0000236655.62920.dc
PMID:16974196
Abstract

Antidepressant use seems to be problematic in bipolar disorder. The dopaminergic agent, bupropion, seems to be equally effective to serotoninergic agents but with greater safety. Methylphenidate is a stimulant medication that is sometimes used as an antidepressant in bipolar adults and is frequently used in children with comorbid bipolar and attention-deficit disorder. There are no data available for the safety of long-term methylphenidate in adults. A retrospective chart review of bipolar patients who received methylphenidate while attending a bipolar clinic was conducted. Data regarding side effects and symptoms were collected. Sixteen charts were reviewed. The mean duration of methylphenidate treatment was 14 months (+/-SD, +/-17.5 months; range, 1-60 months). Five had comorbid attention-deficit disorder, the remainder received the methylphenidate for depression. The mean dose was 16.3 mg/d (+/-SD, +/-8.7 mg/d; range, 5-40 mg/d). Several mild to moderate side effects were reported. Two patients (12.5%) discontinued methylphenidate because of adverse side effects. When available (44% of the sample), general assessment of function increased from (+/-SD) 48.3 +/- 9.9 to 69.3 +/- 10.6 (P = 0.006). Methylphenidate seems to be safe in the naturalistic setting. Controlled studies are needed to confirm its efficacy and safety in bipolar depression.

摘要

在双相情感障碍中,使用抗抑郁药似乎存在问题。多巴胺能药物安非他酮似乎与5-羟色胺能药物效果相当,但安全性更高。哌醋甲酯是一种兴奋剂药物,有时用于双相情感障碍成年患者的抗抑郁治疗,也常用于患有双相情感障碍合并注意力缺陷障碍的儿童。目前尚无关于哌醋甲酯在成人中长期使用安全性的数据。对在双相情感障碍门诊接受哌醋甲酯治疗的双相情感障碍患者进行了一项回顾性病历审查。收集了有关副作用和症状的数据。共审查了16份病历。哌醋甲酯治疗的平均持续时间为14个月(±标准差,±17.5个月;范围为1 - 60个月)。其中5例患有合并注意力缺陷障碍,其余患者接受哌醋甲酯治疗是为了缓解抑郁症状。平均剂量为16.3毫克/天(±标准差,±8.7毫克/天;范围为5 - 40毫克/天)。报告了几种轻度至中度的副作用。两名患者(12.5%)因不良反应而停用哌醋甲酯。在可获取数据的情况下(样本的44%),功能总体评估从(±标准差)48.3±9.9提高到了69.3±10.6(P = 0.006)。在自然环境中,哌醋甲酯似乎是安全的。需要进行对照研究以证实其在双相情感障碍抑郁治疗中的疗效和安全性。

相似文献

1
Naturalistic long-term use of methylphenidate in bipolar disorder.哌醋甲酯在双相情感障碍中的自然主义长期使用。
J Clin Psychopharmacol. 2006 Oct;26(5):516-8. doi: 10.1097/01.jcp.0000236655.62920.dc.
2
Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.双相情感障碍患者辅助使用兴奋剂:残余抑郁和镇静的治疗
Bipolar Disord. 2004 Oct;6(5):416-20. doi: 10.1111/j.1399-5618.2004.00132.x.
3
Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.共病自闭症谱系障碍对注意力缺陷多动障碍儿童兴奋剂反应的影响:一项回顾性和前瞻性有效性研究。
Child Care Health Dev. 2006 Sep;32(5):575-83. doi: 10.1111/j.1365-2214.2006.00631.x.
4
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.OROS 哌甲酯治疗成人注意力缺陷/多动障碍的疗效与安全性:一项随机、安慰剂对照、双盲、平行组、剂量递增研究。
J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.
5
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.控释型哌甲酯能否改善核心症状及执行功能缺陷?针对成人注意力缺陷多动障碍的开放标签试验结果
Curr Med Res Opin. 2006 Dec;22(12):2557-66. doi: 10.1185/030079906X154132.
6
Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.成人注意力缺陷多动障碍中哌甲酯诱发的精神病:3例新病例报告及文献综述
Clin Neuropharmacol. 2010 Jul;33(4):204-6. doi: 10.1097/WNF.0b013e3181e29174.
7
Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.哌甲酯透皮系统在儿童注意力缺陷/多动障碍中的长期耐受性:一项多中心、前瞻性、为期12个月的开放标签、非对照、四项临床试验的III期扩展研究。
Clin Ther. 2009 Aug;31(8):1844-55. doi: 10.1016/j.clinthera.2009.08.002.
8
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.注意缺陷多动障碍儿童及青少年从哌甲酯或苯丙胺转换为托莫西汀的初步耐受性和疗效研究
Clin Ther. 2007 Jun;29(6):1168-77. doi: 10.1016/j.clinthera.2007.06.017.
9
Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.透皮哌甲酯、行为疗法及联合治疗用于多动症儿童
Exp Clin Psychopharmacol. 2005 May;13(2):111-26. doi: 10.1037/1064-1297.13.2.111.
10
Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.注意缺陷多动障碍兴奋剂治疗的安全性:第一部分。
Expert Opin Drug Saf. 2009 Nov;8(6):655-68. doi: 10.1517/14740330903279956.

引用本文的文献

1
Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Coexisting Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments.注意缺陷多动障碍伴双相及酒精使用障碍的三重诊断:临床特征和药物治疗。
Curr Neuropharmacol. 2023;21(7):1467-1476. doi: 10.2174/1570159X20666220830154002.
2
Suicidal and non-suicidal self-injurious behaviour in patients with bipolar disorder and comorbid attention deficit hyperactivity disorder after initiation of central stimulant treatment: a mirror-image study based on the LiSIE retrospective cohort.双相情感障碍合并注意缺陷多动障碍患者在开始使用中枢兴奋剂治疗后出现的自杀及非自杀性自伤行为:一项基于LiSIE回顾性队列的镜像研究
Ther Adv Psychopharmacol. 2020 Aug 6;10:2045125320947502. doi: 10.1177/2045125320947502. eCollection 2020.
3
A Review of Psychostimulants for Adults With Depression.成人抑郁症的精神兴奋剂综述
Fed Pract. 2015 Apr;32(Suppl 3):30S-37S.
4
The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.双相情感障碍的多巴胺假说:现状及对治疗的启示
Mol Psychiatry. 2017 May;22(5):666-679. doi: 10.1038/mp.2017.16. Epub 2017 Mar 14.
5
Use of Stimulants in Bipolar Disorder.双相情感障碍中兴奋剂的使用。
Curr Psychiatry Rep. 2017 Jan;19(1):7. doi: 10.1007/s11920-017-0758-x.
6
Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.评估兴奋剂/类兴奋剂药物和多巴胺激动剂在双相情感障碍治疗中的作用。
Curr Psychiatry Rep. 2013 Aug;15(8):378. doi: 10.1007/s11920-013-0378-z.
7
Current and emerging therapies for the management of bipolar disorders.双相情感障碍治疗的现有及新兴疗法。
J Cent Nerv Syst Dis. 2011 Aug 7;3:189-97. doi: 10.4137/JCNSD.S4441. Print 2011.
8
Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia.双相情感障碍:认知功能障碍和痴呆的临床观点及影响
Depress Res Treat. 2012;2012:275957. doi: 10.1155/2012/275957. Epub 2012 May 28.
9
Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study.兴奋剂能预防患有注意力缺陷多动障碍(ADHD)的青少年出现精神疾病吗?一项为期10年的随访研究。
Pediatrics. 2009 Jul;124(1):71-8. doi: 10.1542/peds.2008-3347.
10
[Manic behavior as an autoregulatory attempt to stabilize vigilance].[躁狂行为作为一种稳定警觉性的自我调节尝试]
Nervenarzt. 2008 Nov;79(11):1283-4, 1286-90. doi: 10.1007/s00115-008-2553-8.